anti-CD70 ADC

Anti-CD70 antibody-drug conjugates (ADCs) are a class of targeted cancer therapeutics designed to deliver cytotoxic payloads specifically to cells expressing the CD70 antigen. CD70, a member of the tumor necrosis factor (TNF) superfamily, is normally expressed on activated T and B cells but is highly overexpressed in various hematologic malignancies (such as multiple myeloma and lymphomas) and solid tumors (notably renal cell carcinoma). These ADCs typically consist of a monoclonal antibody targeting CD70, conjugated via a chemical linker to a potent cytotoxic agent, such as an auristatin (e.g., MMAE, MMAF) or a pyrrolobenzodiazepine (PBD) dimer. Upon binding to CD70 on the tumor cell surface, the ADC is internalized, and the payload is released, leading to cell death. Several companies, including Seagen (formerly Seattle Genetics) and Ambrx, have developed anti-CD70 ADCs for clinical and preclinical evaluation.

Other names

anti-CD70 ADCanti-CD-70 ADCanti-CD 70 ADCCD70-directed antibody-drug conjugateCD-70-directed antibody-drug conjugateCD 70-directed antibody-drug conjugateCD70 ADCCD-70 ADCCD 70 ADCCD70-targeted ADCCD-70-targeted ADCCD 70-targeted ADC